Japan's drugmakers aren't any more immune from generic competition than U.S. pharma companies are. Still the country's second- and third-largest drugmakers are predicting sales growth this year, even as low-cost copies drain away sales of their key products. New drugs are coming in to pick up the slack, the companies said.
India's largest generic drugmaker blamed a 90% drop in first-quarter profit on the fact it just couldn't match the same period last year when it launched its exclusive generic version of Lipitor, the world's best-selling drug.
After a pair of trial setbacks with a separate program from ArQule, Japan-based drugmaker Daiichi Sankyo has decided to jettison an alliance with the Woburn, MA-based drug developer on an early-stage compound known as ARQ 092.
Three continents, three drugmakers, three lenses for viewing pharma's future. Which gives the clearest glimpse of Pharma Next? You decide.
Daiichi Sankyo is the latest drugmaker to find itself in the hot seat for alleged gender bias. Six sales reps have sued the Japanese company's U.S. unit, claiming they lost pay, promotions--and sometimes their jobs. They're aiming for class action status and $100 million in damages.
Mitsui, a Japanese conglomerate whose investments run from steel to luxury goods, has upped its stake in Indian API maker Arch Pharmalabs , saying it likes the future of drugmaking.
ArQule ($ARQL) suffered another failure with its top anti-cancer contender tivantinib. This time the experimental kinase inhibitor fell short in a midstage study in patients with aggressive cases of colorectal cancer, a fresh setback in a program already injured from efficacy concerns.
With the steady (and very loud) drumbeat of bad news this year about the patent cliff's toll on pharma sales and earnings, investing in the industry hasn't been a nonstop party. Still, the sector has outperformed major indices, and some stellar players have emerged. Of course, huge disappointments have cropped up, too. Read the report >>
It's the endgame for 2012 election candidates--and for supporters that have shelled out cash to support their bids for votes. As usual, the pharma business is right there in the fray, with political action committees and employees donating hundreds of thousands, if not millions.
ArQule and its partner Daiichi Sankyo revealed some depressing news about their late-stage program for the closely watched cMET inhibitor called tivantinib or ARQ 197 in patients with non-small cell lung cancer.